Hologic (NASDAQ:HOLX) Issues Earnings Results, Beats Expectations By $0.01 EPS

Hologic (NASDAQ:HOLX) issued its quarterly earnings results on Wednesday. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01, Zacks reports. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic updated its Q2 2025 guidance to 1.000-1.030 EPS and its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $64.79 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic has a one year low of $64.87 and a one year high of $84.67. The firm has a market capitalization of $14.63 billion, a P/E ratio of 19.50, a PEG ratio of 2.35 and a beta of 0.98. The company’s fifty day moving average is $72.63 and its two-hundred day moving average is $77.86.

Analysts Set New Price Targets

Several research analysts recently weighed in on HOLX shares. Stephens restated an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Thursday. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research note on Monday. Finally, Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective on the stock. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.